20 results about "Pattern recognition receptor" patented technology

Methods are provided for reprogramming M2-like macrophages to M1-like macrophages, which reverses the proinflammatory to anti-inflammatory shift observed during the course of certain cancers, co-administered with one or more types of engineered cells such as, without limitation, CAR T-cells, engineered natural killer cells, engineered stem cells or the like. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and / or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for cancers.

The present invention relates to an immunogenic construct with the capability to activate the mammalian immune system. In particular, the present invention relates to an immunogenic construct comprising bacterial proteins or fragments thereof that can both target and activate immune cells through interaction with pattern recognition receptors (PRR) expressed on the immune cells.

Compounds, pharmaceutical compositions and methods are provided for reprogramming M2-like macrophages to M1-like macrophages, which reverses the antifibrotic to profibrotic shift observed during the course of fibrotic diseases and certain cancers. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and / or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for fibrotic diseases and / or cancers.

The invention provides the design of an Innate Super Enager (ISE) and a Complete Immune Antibody (CIA) as well as a preparation method and application of the Innate Super Enager (ISE) and the Complete Immune Antibody (CIA). The innate immune super connector contains an antibody or a ligand which connects and activates innate immune cells, or a cytokine which stimulates proliferation of the innate immune cells, or a pattern recognition receptor (PRR) agonist. The innate immune super connector can be used independently, can also be combined with other immune antibodies, or can be further connected with one or more postnatal immune antibodies or ligands to form a complete immune antibody. The complete immune antibody has two forms: (1) an end N of the innate immune super connector is connected with an acquired immune antibody or a tumor antigen antibody; and (2) connecting the C end or the N end of the acquired immune antibody or the tumor antigen antibody to an innate immune super connector.

Disclosed are compounds and compositions for inhibiting the expression of a pattern recognition receptor (e.g., STING), and methods of use thereof.

The application belongs to the field of tea polysaccharide research, and discloses a Zijuan tea polysaccharide ZTPW with immunoregulatory activity, and a preparation method and application thereof. The ZTPW is a uniform polysaccharide obtained by hot water extraction and alcohol precipitation of Zijuan tea leaves, and separation and purification through an ion exchange column and a gel column, the main repeating unit structure of which is shown in the following, and the weight average molecular weight thereof is 7.73 kDa. Through in vitro immunoregulatory activity research, the ZTPW can be recognized by pattern recognition receptors TLR2 and TLR4 to activate macrophages, significantly enhance the activity of mouse monocyte macrophage RAW264.7 cells, and mediate the production of NO and cytokines of mouse monocyte macrophage RAW264.7 through MAPKs and NF-kappa B signal pathway, so as to play an immunoregulatory role. The polysaccharide can be used as a potential immunoregulator for the development of functional food or medicine.

The invention discloses application of Dectin-1 as a biomarker in preparation of a renal fibrosis diagnostic reagent or kit, and belongs to the field of biological medicine. And Dectin-1 is a member of a pattern recognition receptor C-type lectin family. According to the invention, Dectin-1 immunofluorescent staining is carried out on kidney tissues of patients with chronic kidney diseases, and observation shows that the number of Dectin-1 + cells in fibrosis kidneys is more. Dectin-1 immunofluorescence staining is further carried out in the kidney tissue of the patient with the IgA nephropathy, and it is found that the number of Dectin-1 + cells in the kidney tissue of the patient with the IgA nephropathy is in positive correlation with the renal fibrosis degree. The results show that the reagent for detecting the expression level of the Dectin-1 in the kidney cells can be used for preparing the kit for diagnosing the kidney fibrosis, and the diagnosis result has high sensitivity and specificity.

Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.

Therapeutic modalities are provided for targeting adoptive cellular therapies to specific sites of disease, involving the use of specific repertoirs of PRR ligands. In effect, innate immune system signaling is provoked so as to facilitate the homing of adoptive immune cells to sites of disease, for example to the site of a solid tumor.

The present disclosure relates, according to some embodiments, to compositions, methods, kits, and systems for detecting double-stranded RNA that include, for example, contacting a pattern recognition receptor (e.g., an oligoadenylate synthase 1; an Av cGAS-like receptor) with an RNA comprising or potentially comprising double-stranded RNA to conditionally produce (e.g., if dsRNA is present) pyrophosphate and, optionally, an oligonucleotide.

Compounds, pharmaceutical compositions and methods are provided for reprogramming M2-like macrophages to M1-like macrophages, which reverses the antifibrotic to profibrotic shift observed during the course of fibrotic diseases and certain cancers. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and / or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for fibrotic diseases and / or cancers.

The invention belongs to the technical field of gene engineering, and relates to application of an apple pattern recognition receptor gene MdRE02 in regulation and control of plant disease resistance. The nucleotide sequence of the apple pattern recognition receptor gene MdRE02 is as shown in SEQ ID NO.1, the MdRE02 gene is silenced in apples, the expression of an immune gene induced by a pathogen-related molecular pattern VmE02 is remarkably reduced, and the disease resistance to valsa mali of apple trees is remarkably weakened. Through overexpression of the MdRE02 gene in the tobacco mutant re02, cell necrosis and active oxygen bursting induced by the VmE02 can be recovered, which indicates that the MdRE02 is a pattern recognition receptor for recognizing the VmE02. By overexpressing the MdRE02 gene in tobacco mutants re02 and oilseed rape, the resistance of the MdRE02 gene to sclerotinia sclerotiorum can be remarkably improved. The results show that the MdRE02 gene can be used for disease-resistant breeding and disease prevention and control of valsa ceratosperma and sclerotinia sclerotiorum of apple trees.

Disclosed are pharmaceutical compositions formulated from immunomodulators formed from glycogen nanoparticles, such as monodisperse phytoglycogen nanoparticles, complexed with a pattern recognition receptor agonist, such as a TLR agonist which can be poly I:C. Also disclosed are methods of treating solid tumor cancers using the described immunomodulators, and uses of the immunomodulators to treat solid tumor cancers and to manufacture medicaments to treat solid tumor cancers.

Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.

The invention discloses preparation and application of a novel immune agonist, and relates to the technical field of biological medicine, the novel immune agonist is applied to an immune response enhancement process in tumor immunotherapy, chronic virus infection treatment and vaccine adjuvant development, namely, a TLR9 mode recognition receptor on the surface of an immune cell is activated, and the immune response is enhanced. The anti-tumor or anti-infection immune response of the body is enhanced. According to the preparation and the application of the novel immune agonist, through chemical modification, targeted modification treatment is fully performed on sites possibly acted by enzyme, so that the resistance of a nucleic acid TLR9 agonist to nuclease is enhanced, the nucleic acid TLR9 agonist is not easy to degrade, a long-acting preparation technology is introduced, the circulation time of a drug in a body is prolonged through PEG modification, and the novel immune agonist can be used for preparing a novel immune agonist. The chance of enzyme degradation is further reduced, the stability and half-life period of the nucleic acid TLR9 agonist in vivo are remarkably improved, and a more lasting and effective anti-tumor or anti-infection immune response enhancement effect is achieved.

The invention discloses a method for improving resistance of natural enemy mites to beauveria bassiana, and relates to the technical field of resistance research of biocontrol natural enemy. The method comprises the following steps: S1, feeding natural enemy mites, wherein the natural enemy mites are predatory mites; s2, carrying out starvation treatment on natural enemy mites; s3, after the natural enemy mites are subjected to starvation treatment, beta-1. 3-glucan is adopted for feeding; s4, detecting the resistance of the beauveria bassiana after feeding treatment in S3, determining the survival rate of the natural enemy mites, and verifying the improvement rate. The background mechanism is clear, up-regulation expression of a PGRP (Protein Growth Reduction Protein) of a Neoseiulus barkeri pattern recognition receptor is induced in a targeted manner based on beta-1. 3-glucan, so that immune response of a mite body is activated in advance, and the resistance to biocontrol fungi is obtained in a short time through an'immune memory 'principle; the operation time is short, and the fitness cost caused by long-term domestication is avoided; and the resistance of the predatory mites to biocontrol fungi can be accurately improved, so that the tolerance of the predatory mites in different batches is stable.

The present invention provides a design of an innate super engager (ISE) and a complete immune antibody (CIA), a preparation method therefor, and use thereof. The innate super engager comprises an antibody or ligand that connects and activates innate immune cells, or a cytokine that stimulates the proliferation of innate immune cells, or a pattern recognition receptor (PRR) agonist. The innate super engager can be used alone or in combination with other immune antibodies, or can be further linked with one or more acquired immune antibodies or ligands to form a complete immune antibody. The complete immune antibody has two forms: (1) an acquired immune antibody or a tumor antigen antibody is connected to the N terminal of the innate super engager; and (2) the innate super engager is connected to the C terminal or N terminal of the acquired immune antibody or the tumor antigen antibody.

The invention belongs to the technical field of plant genetic engineering, and relates to application of an arabidopsis thaliana-derived pattern recognition receptor AtRLP30 gene in improving the fungal disease resistance of plants. The nucleotide sequence of the AtRLP30 gene is as shown in SEQ ID NO. 1. By constructing a plant expression vector containing AtRLP30 and performing overexpression in the plant, the resistance of the plant to fungal pathogen infection can be remarkably improved. Preferably, the fungi comprise ascospora poplar and ascopolyspora poplar, and the fungi comprise ascospora poplar. Experimental results show that after the AtRLP30 is overexpressed in the poplar, the transgenic plant shows stronger active oxygen accumulation, MAPK signal activation and defense related gene expression after being infected by pathogenic bacteria, and the biomass and scab area of the pathogenic bacteria are remarkably reduced. The invention proves that the AtRLP30 has the function of enhancing the fungal disease resistance in the woody plant, and provides a new gene resource and technical approach for improving the forest disease resistance by utilizing a pattern recognition receptor.

Embodiments of the present disclosure generally relate to compositions and methods for treating musculoskeletal disorders or conditions, such as osteoarthritis (OA). Specifically, the compositions and methods include activating mesenchymal stromal cell (MSC) with a stimulator of interferon gene (STING) agonist or a toll like receptor (TLR) agonist. A method of treating a musculoskeletal disorder or condition in a subject is disclosed. The method includes administering to the subject a composition including a MSC. The MSC include an activated signaling pathway downstream of (i) STING and / or (ii) TLR3. In another embodiment, a composition for treating musculoskeletal disorders or conditions in a patient is disclosed. The composition includes a MSC with pattern recognition receptors (PRR), wherein the PRR comprises an activated STING pathway, an activated a TLR3 pathway, or a combination thereof.

The purpose of the present invention is to provide a medicine useful for treating HIV infection by using compounds having different mechanisms in combination with kick and kill therapy. A medicine characterized by being a combination of (A) a polynucleotide or polypeptide that induces an anti-HIV Tat antibody that inhibits the activity of HIV Tat protein secreted from HIV-infected cells, and (B) a pattern recognition receptor agonist that induces type I IFN, is useful for the treatment, etc., of HIV infection.